A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
- Conditions
- MedDRA version: 9.1Level: LLTClassification code 10066490Term: Progression of non small cell lung canceron-small-cell-lung-cancer
- Registration Number
- EUCTR2006-006626-26-DE
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 650
Patients are eligible for this second-line therapy study if they have recurrent or refractory (progression through at
least two cycles of a given chemotherapeutic
regimen) NSCLC following standard first-line chemotherapy or chemoradiotherapy.
• Signed written informed consent
• Cytologically or histologically confirmed NSCLC
Patients had to have histologically or cytologically confirmed NSCLC. Tumors of mixed histology were
categorized by the predominant cell type unless small cell elements were present, in which case the patient
was not eligible for study participation. Cytologic or histologic elements have been established on metastatic
tumor aspirates or biopsy. Patients with squamous cell carcinoma were eligible provided that their disease
was extrathoracic or that their intrathoracic disease consists of peripheral lesions only. A peripheral lesion was
defined as a lesion (or lesions) in which the epicenter of the tumor was = 2 cm from the costal or diaphragmatic
pleura in a 3-dimensional orientation based on each lobe of the lung, and > 2 cm from the trachea, main,
and lobar bronchi. Squamous cell carcinoma patients were eligible for study participation irrespective of
the proximity of their adenopathy to the costal or diaphragmatic pleura or major airways. Patients with hilar
adenopathy were eligible for study participation. Patients with squamous cell carcinoma had to have a copy of
the screening computed tomography (CT) or magnetic resonance imaging (MRI) scans (either as copy films or
digital images) reviewed by Genentech or its designee prior to randomization. Patients were not randomized until
Genentech or its designee confirmed eligibility. Patients with a history of brain metastases were eligible for study
participation, as long as their brain metastases had been treated and they did not have an ongoing requirement
for treatment with dexamethasone at screening. Treatment had to be with WBRT (e.g., 3000 cGy over 2 weeks)
and might include neurosurgery, or stereotactic radiosurgery. Radiotherapy and stereotactic radiosurgery had to
be completed at least 4 weeks prior to Day 0 (see Section 4.3.2). Neurosurgery had to be completed at least 24
weeks prior to Day 0, and brain biopsy must be completed at least 12 weeks prior to Day 0.
• Clinical or radiographic progression during or after first-line chemotherapy
or chemoradiotherapy for NSCLC. Patients receiving neo-adjuvant and adjuvant therapy for Stage I–IIIa disease
prior to their first-line regimen were eligible for study participation provided they had also received first-line
therapy (for unresectable, metastatic disease) and had demonstrated progression during or after that first-line
therapy.
• Consent to provide archival tissue for analysis was required for participation in this study. Patients who
consented to provide tissue but whose archival tissue was found to be inadequate (e.g., stained slides) remained
eligible for study participation.
• ECOG performance status of 0, 1, or 2.
• Age = 18 years
• Use of an acceptable means of contraception for men and women of childbearing potential
• INR no greater than 1.3 and an aPTT no greater than the upper limits of normal within 28 days prior to
enrollment for patients not on low-molecular-weight heparin or fondaparinux. Patients on low-molecular-weight
heparin or fondaparinux were not required to meet INR or aPTT limits.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) y
Patients meeting any of the following criteria were ineligible for study entry:
• Squamous cell carcinoma, except for patients with no intrathoracic disease or small peripheral lesions only.
• Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent
Angiogenesis inhibitors include (but are not limited to) bevacizumab, thalidomide, CP 547632, SU 11248, and
PTK 787.
• Systemic chemotherapy, radiotherapy, or investigational treatment within 28 days prior to randomization. Local
palliative radiotherapy within 14 days prior to randomization or persistent adverse effects from radiotherapy that
have not resolved to Grade 2 or less following completion of treatment
• Whole brain radiotherapy or stereotactic radiosurgery for brain metastases within 4 weeks of Day 0
• Neurosurgery for brain metastases within 24 weeks of Day 0
• Brain biopsy within 12 weeks of Day 0
• Current use of dexamethasone for treatment associated with brain metastases
• History of gross hemoptysis (defined as bright red blood of at least 1/2 teaspoon or 2.5 mL per episode) within 3
months prior to randomization unless definitively treated with surgery or radiation
• History of any of the following within 6 months prior to Day 0: serious systemic disease, including myocardial
infarction, uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100
mmHg taken per the JNC 7 guidelines, unstable angina, New York Heart Association (NYHA) Grade 2 or
greater CHF, unstable symptomatic arrhythmia requiring medication (patients with chronic atrial arrhythmia,
i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), clinically significant peripheral
vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess. Patients with
evidence of hypertension during study screening were to be evaluated for uncontrolled hypertension in
accordance with the JNC 7 guidelines.
• Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior
to randomization
• CNS bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic) within the last 6 months
• Progressive neurologic symptoms in patients with a history of brain metastases
• Full-dose anticoagulation with warfarin. Patients who required full-dose anticoagulation could be treated with
low-molecular-weight heparin or fondaparinux. Patients fully anticoagulated with warfarin during the study were
discontinued from bevacizumab/placebo.
• Chronic daily use of aspirin (> 325 mg/day) or other full-dose NSAIDs with anti-platelet activity. Treatment
with other antiplatelet agents (e.g., dipyridamole, ticlopidine, clopidogrel, and/or cilostazol) was permitted.
• In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
(placement of a central line is not considered surgery, and could be placed on the same day as study drug
administration)
• Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior to randomization
• Anticipation of need for a major surgical procedure during the course of the study
• Serious, non-healing wound, ulcer, or bone fracture
• Inability to take oral medication or requirement for IV alimentation or total parenteral nutrition with lipids, or
prior surgical procedures affecting absorption
• Any of the following abnormal hematologic value
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method